The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | The effect of COVID-19 on CLL patient experiences
Zack Pemberton-Whiteley, Leukemia Care, Worcester, UK, discusses the findings of a study investigating the experiences of patients with chronic lymphocytic leukemia (CLL) during the COVID-19 pandemic. Mr Pemberton-Whiteley reports that there were high vaccination and shielding rates observed amongst patients with CLL, with a significant proportion of patients adhering to stay-at-home guidelines. Additionally, medical appointments were mostly conducted over the phone; however, more than half of patients expressed a desire for input regarding future treatment. A parallel clinical survey found that around 44 patients contracted COVID-19, and of those 12 were admitted to hospital, 50% of whom had opted not to shield. This highlights the effect of shielding in reducing the incidence of COVID-19 infection. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL) congress.
Disclosures
Zack Pemberton-Whiteley is the CEO of Leukemia Care, UK, the Chair of the Acute Leukemia Advocates Network (ALAN), and has received institutional grant funding and/or honoraria from AbbVie, Agios, Amgen, Astellas, Autolus, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Incyte, Jazz, Janssen, Kite, Kyowa Kirin, Mallinckrodt, Novartis, Pfizer, Roche, Servier and Takeda.
